Kyntra Bio Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw revenue growth and reduced expenses, with key clinical programs advancing as planned. FG-3246/FG-3180 phase II trial is on track for interim analysis in Q4 2026, and roxadustat is set for phase III initiation in H2 2026. Cash runway extends into 2028.
-
The company has transformed its business, repaid debt, and now focuses on advancing its ADC FG-3246 and PET imaging agent FG-3180 in mCRPC, with interim Phase II data expected in H2 2024. Roxadustat is being prepared for a Phase III trial in lower-risk MDS, with funding or partnership options under evaluation.
-
Kyntra Bio highlighted its transformation, extended cash runway, and focus on two lead assets: FG-3246/FG-3180 for prostate cancer and Roxadustat for lower risk MDS. Key clinical trials are underway, with interim results for prostate cancer expected in H2 2024 and a new phase III MDS trial pending FDA feedback.
-
Kyntra Bio, following its rebranding and strategic refocus, is advancing a novel CD46-targeting ADC and companion PET imaging agent in mCRPC, with interim phase II results expected this year. Roxadustat is poised for phase III in MDS, supported by FDA alignment and orphan drug status.
Fiscal Year 2025
-
2025 marked a transformational year with the sale of FibroGen China, debt repayment, and rebranding, extending cash runway into 2028. FG-3246 and FG-3180 advanced in mCRPC with promising early data, while roxadustat progressed in MDS with orphan drug status and a phase III trial planned for late 2026.
-
Q3 2025 saw a transformative $220M China sale, major cost reductions, and a cash runway into 2028. FG-3246 and Roxadustat clinical programs advanced, with key trial milestones expected in 2026. Roxadustat phase III trial funding may require additional capital or a partner.
-
A transformative sale of China operations has extended the cash runway into 2028 and eliminated debt. The pipeline features a novel ADC for prostate cancer with promising early results and a phase 2 trial starting soon, while roxadustat advances toward a phase 3 trial in lower risk MDS.
-
Q2 2025 saw a transformative China sale boosting cash runway into 2028, significant cost reductions, and progress on FG-3246 and roxadustat clinical programs. Phase II and III trials are on track, with strong financial positioning and multiple near-term catalysts.
-
Divestiture of China operations for $185M boosts cash runway into H2 2027 and enables payoff of debt. Focus shifts to U.S. pipeline, with phase II trials for FG-3246/FG-3180 in MCRPC and regulatory progress for roxadustat in MDS. Q1 2025 saw reduced losses and positive cash flow.
-
The sale of China operations for ~$160 million transforms the organization into a U.S.-focused oncology innovator, extends its cash runway into 2027, and enables advancement of key assets FG-3246 and FG-3180 for mCRPC. Roxadustat's U.S. development for MDS anemia will be clarified after an FDA meeting in 2025.
Fiscal Year 2024
-
Divestiture of China operations for $160M extends cash runway into 2027 and enables focus on U.S. oncology and anemia assets. 2024 saw significant cost reductions and narrowed net loss, with key clinical milestones for FG-3246/FG-3180 and roxadustat expected in 2025.
-
Q3 2024 saw 15% revenue growth and a 57% increase in Roxadustat China net product revenue, with strong cost reductions and a net loss improvement to $17.1M. The company maintains robust cash reserves, advances its oncology pipeline, and expects continued Roxadustat growth in China and Europe.
-
FG-3246, a novel CD46-targeted ADC for mCRPC, is advancing with phase II trials and integrated PET46 biomarker screening, while roxadustat continues robust revenue growth in China and explores new partnership and indication opportunities. Cash reserves support operations into 2026.
-
Q2 2024 saw strong revenue growth driven by roxadustat in China, offsetting the discontinuation of pamrevlumab after failed trials. Strategic focus shifts to FG-3246 and continued expansion of roxadustat, with cost reductions and a solid cash position supporting operations into 2026.
-
Upcoming catalysts include two pivotal pamrevlumab readouts in pancreatic cancer, continued strong growth for roxadustat in China, and phase 2/3 trials for the CD46 ADC in prostate cancer. The pipeline is focused on oncology, with cash runway into 2026 and flexible partnering strategies.